US92532F1003
US92532F1003
Vertex Pharmaceuticals Incorpor
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 129.2B EUR | 125.85B EUR | 113.49B EUR | 115.15B EUR |
Enterprise Value | 121.68B EUR | 121.68B EUR | 109.99B EUR | 112.1B EUR |
Valuation Multiples | ||||
Trailing P/E | 29.71x | 28.57x | 26.16x | 34.82x |
Forward P/E | 25.37x | -- | -- | -- |
Price to Sales | 10.26x | 10x | 9.29x | 12.47x |
Price to Book | 6.38x | 6.22x | 5.86x | 6.17x |
EV/Revenue | 9.67x | 9.67x | 9x | 12.14x |
EV/EBITDA | 23.86x | 23.11x | 21.45x | 28.51x |
Price to FCF (P/FCF) | 49.17x | 33.15x | 30.59x | 47.67x |
EV/FCF | 46.3x | 32.05x | 29.64x | 46.4x |
FCF Yield | 2.03% | 3.02% | 3.27% | 2.1% |